VDR and secondary hyperparathyroidism: Secondly, a 1-year RCT conducted by Shoji et al. compared the calcimimetic etelcalcetide with the vitamin D receptor activator maxacalcitol in a cohort of 321 hemodialysis patients with secondary hyperparathyroidism.